🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "major milestone" in the battle against superbug strains of the infection, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are observed in Africa and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The WHO has classified it as a "priority pathogen". Ongoing monitoring showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is employed against UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This approval represents a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

As per results published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an equal footing with the typical regimen, which involves an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to license and sell the drug in numerous regions with limited resources.

Medical professionals directly involved have voiced optimism. Having a easy-to-administer therapy like this is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of highly drug-resistant gonorrhoea around the world.